SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Mogensen H)
 

Sökning: WFRF:(Mogensen H) > Reduction in albumi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003858naa a2200625 4500
001oai:gup.ub.gu.se/56039
003SwePub
008240528s2005 | |||||||||||000 ||eng|
024a https://gup.ub.gu.se/publication/560392 URI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Ibsen, H.4 aut
2451 0a Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study
264 1c 2005
520 a Few data are available to clarify whether changes in albuminuria over time translate to changes in cardiovascular risk. The aim of the present study was to examine whether changes in albuminuria during 4.8 years of antihypertensive treatment were related to changes in risk in 8206 patients with hypertension and left ventricular hypertrophy in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Urinary albumin/creatinine ratio (UACR) was measured at baseline and annually. Time-varying albuminuria was closely related to risk for the primary composite end point (ie, when UACR decreased during treatment, risk was reduced accordingly). When the population was divided according to median baseline value (1.21 mg/mmol) and median year 1 UACR (0.67 mg/mmol), risk increased stepwise and significantly for the primary composite end point from those with low baseline/low year 1 (5.5%), to low baseline/high year 1 (8.6%), to high baseline/low year 1 (9.4%), and to high baseline/high year 1 (13.5%) values. Similar significant, stepwise increases in risk were seen for the components of the primary composite end point (cardiovascular mortality, stroke, and myocardial infarction). The observation that changes in UACR during antihypertensive treatment over time translated to changes in risk for cardiovascular morbidity and mortality was not explained by in-treatment level of blood pressure. We propose that monitoring of albuminuria should be an integrated part of the management of hypertension. If albuminuria is not decreased by the patient's current antihypertensive and other treatment, further intervention directed toward blood pressure control and other modifiable risks should be considered.
653 a Aged
653 a Aged
653 a 80 and over
653 a Albuminuria/*physiopathology
653 a Antihypertensive Agents/*therapeutic use
653 a Atenolol/therapeutic use
653 a Cardiovascular Diseases/*etiology
653 a Creatinine/urine
653 a Female
653 a Humans
653 a Hypertension/*drug therapy/*urine
653 a Losartan/*therapeutic use
653 a Male
653 a Middle Aged
653 a Predictive Value of Tests
653 a Proportional Hazards Models
653 a Risk Factors
653 a Severity of Illness Index
700a Olsen, M. H.4 aut
700a Wachtell, K.4 aut
700a Borch-Johnsen, K.4 aut
700a Lindholm, L. H.4 aut
700a Mogensen, C. E.4 aut
700a Dahlöf, Björn,d 1953u Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute4 aut0 (Swepub:gu)xdahbj
700a Devereux, R. B.4 aut
700a de Faire, U.4 aut
700a Fyhrquist, F.4 aut
700a Julius, S.4 aut
700a Kjeldsen, S. E.4 aut
700a Lederballe-Pedersen, O.4 aut
700a Nieminen, M. S.4 aut
700a Omvik, P.4 aut
700a Oparil, S.4 aut
700a Wan, Y.4 aut
710a Göteborgs universitetb Hjärt-kärlinstitutionen4 org
773t Hypertensiong 45:2, s. 198-202q 45:2<198-202x 1524-4563
8564 8u https://gup.ub.gu.se/publication/56039

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy